Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Silo Pharma (SILO) over the last 13 years, with Q3 2025 value amounting to -$1.1 million.

  • Silo Pharma's Net Income towards Common Stockholders fell 1955.44% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.1 million, marking a year-over-year decrease of 3669.93%. This contributed to the annual value of -$4.4 million for FY2024, which is 621160.92% down from last year.
  • Latest data reveals that Silo Pharma reported Net Income towards Common Stockholders of -$1.1 million as of Q3 2025, which was down 1955.44% from -$1.2 million recorded in Q2 2025.
  • In the past 5 years, Silo Pharma's Net Income towards Common Stockholders ranged from a high of $6.4 million in Q3 2021 and a low of -$2.3 million during Q1 2021
  • Its 5-year average for Net Income towards Common Stockholders is -$706945.6, with a median of -$983246.0 in 2022.
  • Data for Silo Pharma's Net Income towards Common Stockholders shows a peak YoY increase of 110744.23% (in 2021) and a maximum YoY decrease of 87736.45% (in 2021) over the last 5 years.
  • Over the past 5 years, Silo Pharma's Net Income towards Common Stockholders (Quarter) stood at -$835319.0 in 2021, then plummeted by 99.07% to -$1.7 million in 2022, then surged by 36.76% to -$1.1 million in 2023, then plummeted by 64.57% to -$1.7 million in 2024, then soared by 35.84% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q3 2025, -$1.2 million for Q2 2025, and -$1.0 million during Q1 2025.